Impact of improving negative symptoms on functioning in patients with schizophrenia: a post-hoc analysis of a proof-of-concept study

被引:0
|
作者
Blaettler, T. [1 ]
Edgar, C. [2 ]
Garibaldi, G. [3 ]
机构
[1] F Hoffmann La Roche Ltd, PDND Clin Dev CNS, Basel, Switzerland
[2] Roche Prod Ltd, Welwyn Garden City, England
[3] F Hoffmann La Roche Ltd, CNS Clin Dev, Basel, Switzerland
关键词
D O I
10.1016/S0924-977X(12)70474-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:S310 / S310
页数:1
相关论文
共 50 条
  • [1] A post-hoc analysis of the negative symptom factor score in a proof-of-concept study of glycine reuptake inhibitor bitopertin in schizophrenia
    Umbricht, D.
    Lentz, E.
    Santarelli, L.
    Lalonde, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S311 - S311
  • [2] A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA
    Umbricht, Daniel
    Lentz, Ellen L.
    Santarelli, Luca
    Lalonde, Justine
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S360 - S360
  • [4] The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
    Laszlovszky, I.
    Dombi, Z. B.
    Balogh, A.
    Barabassy, A.
    Vass, G.
    Szatmari, B.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2021, 64 : S533 - S533
  • [5] Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone
    Sebe, B.
    Barabassy, A.
    Laszlovszky, I.
    Szatmari, B.
    Harsanyi, J.
    Acsai, K.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S275 - S275
  • [6] Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
    Marx, Christine E.
    Keefe, Richard S. E.
    Buchanan, Robert W.
    Hamer, Robert M.
    Kilts, Jason D.
    Bradford, Daniel W.
    Strauss, Jennifer L.
    Naylor, Jennifer C.
    Payne, Victoria M.
    Lieberman, Jeffrey A.
    Savitz, Adam J.
    Leimone, Linda A.
    Dunn, Lawrence
    Porcu, Patrizia
    Morrow, A. Leslie
    Shampine, Lawrence J.
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (08) : 1885 - 1903
  • [7] Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia
    Christine E Marx
    Richard S E Keefe
    Robert W Buchanan
    Robert M Hamer
    Jason D Kilts
    Daniel W Bradford
    Jennifer L Strauss
    Jennifer C Naylor
    Victoria M Payne
    Jeffrey A Lieberman
    Adam J Savitz
    Linda A Leimone
    Lawrence Dunn
    Patrizia Porcu
    A Leslie Morrow
    Lawrence J Shampine
    Neuropsychopharmacology, 2009, 34 : 1885 - 1903
  • [8] Proof-of-concept trial with the neurosterold pregnenolone targeting neurocognitive and negative symptoms in schizophrenia
    Marx, Christine E.
    Keefe, Richard S.
    Leimone, Linda A.
    Hamer, Robert M.
    Bradford, Daniel W.
    Dunn, Lawrence
    Payne, Victoria M.
    Naylor, Jennifer C.
    Savitz, Adam J.
    Strauss, Jennifer L.
    Lieberman, Jeffrey A.
    Shampine, Lawrence J.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 13S - 13S
  • [9] The use of mean circulatory filling pressure analogue for monitoring hemodynamic coherence: A post-hoc analysis of the SPARSE data and proof-of-concept study
    Laou, Eleni
    Papagiannakis, Nikolaos
    Sarchosi, Smaragdi
    Kleisiaris, Konstantinos
    Apostolopoulou, Aggeliki
    Syngelou, Vasiliki
    Kakagianni, Maria
    Christopoulos, Agamemnon
    Ntalarizou, Nicoleta
    Chalkias, Athanasios
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2023, 84 (01) : 19 - 32
  • [10] Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study
    Werth, Victoria P.
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Levine, Todd
    Kopasz, Norbert
    Worm, Margitta
    Bata-Csorgo, Zsuzsanna
    ECLINICALMEDICINE, 2023, 64